Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment.


Journal

Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 15 07 2019
accepted: 25 11 2019
pubmed: 12 12 2019
medline: 12 8 2020
entrez: 12 12 2019
Statut: ppublish

Résumé

5-methoxy-N,N-dimethyltryptamine is a psychotropic substance found in various plant and animal species and is synthetically produced. 5-methoxy-N,N-dimethyltryptamine is used in naturalistic settings for spiritual exploration, recreation, or to address negative affect and mood problems. However, scientific knowledge on the effects of 5-methoxy-N,N-dimethyltryptamine in humans is scarce. The first objective was to assess the effects of inhalation of vaporized synthetic 5-methoxy-N,N-dimethyltryptamine on neuroendocrine markers. The second objective was to assess effects of the substance on affect and mindfulness. In addition, we assessed whether ratings of subjective measures were associated with changes in stress biomarkers (i.e., cortisol) and immune response (i.e., IL-6, CRP, IL-1β), as well as the acute psychedelic experience. Assessments (baseline, immediately post-session, and 7-day follow-up) were made in 11 participants. Salivary samples were collected at baseline and post-session and analyzed by high-sensitivity enzyme-linked immunosorbent assay (ELISA). 5-methoxy-N,N-dimethyltryptamine significantly increased cortisol levels and decreased IL-6 concentrations in saliva immediately post-session. These changes were not correlated to ratings of mental health or the psychedelic experience. Relative to baseline, ratings of non-judgment significantly increased, and ratings of depression decreased immediately post-session and at follow-up. Ratings of anxiety and stress decreased from baseline to 7-day follow-up. Participant ratings of the psychedelic experience correlated negatively with ratings of affect and positively with ratings of non-judgment. Inhalation of vaporized synthetic 5-methoxy-N,N-dimethyltryptamine produced significant changes in inflammatory markers, improved affect, and non-judgment in volunteers. Future research should examine the effect of 5-methoxy-N,N-dimethyltryptamineamine with healthy volunteers in a controlled laboratory setting.

Identifiants

pubmed: 31822925
doi: 10.1007/s00213-019-05414-w
pii: 10.1007/s00213-019-05414-w
pmc: PMC7036074
doi:

Substances chimiques

Hallucinogens 0
IL6 protein, human 0
Interleukin-6 0
Psychotropic Drugs 0
Hydrocortisone WI4X0X7BPJ
N,N-Dimethyltryptamine WUB601BHAA

Types de publication

Journal Article Observational Study Pragmatic Clinical Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

773-785

Subventions

Organisme : NIDA NIH HHS
ID : T32 DA007209
Pays : United States
Organisme : NIH HHS
ID : #T32DA07209
Pays : United States

Références

Entropy (Basel). 2019 Jan 30;21(2):
pubmed: 33266844
PLoS One. 2014 Aug 29;9(8):e106533
pubmed: 25171370
Nat Rev Immunol. 2018 Dec;18(12):773-789
pubmed: 30254251
J Psychoactive Drugs. 2001 Oct-Dec;33(4):403-7
pubmed: 11824699
Lancet Psychiatry. 2015 Mar;2(3):258-270
pubmed: 26359903
Nat Rev Immunol. 2016 Jan;16(1):22-34
pubmed: 26711676
J Psychopharmacol. 2018 Jul;32(7):779-792
pubmed: 29708042
J Psychopharmacol. 2015 Mar;29(3):289-99
pubmed: 25586396
Pharmacol Ther. 2004 Feb;101(2):131-81
pubmed: 14761703
Brain Behav Immun. 2010 May;24(4):558-63
pubmed: 20043983
PLoS One. 2013 Oct 02;8(10):e75426
pubmed: 24098382
Pharmacopsychiatry. 1998 Jul;31 Suppl 2:80-4
pubmed: 9754838
Nat Rev Immunol. 2011 Aug 05;11(9):607-15
pubmed: 21818123
World J Diabetes. 2014 Dec 15;5(6):730-8
pubmed: 25512775
J Psychopharmacol. 2016 Dec;30(12):1181-1197
pubmed: 27909165
Curr Drug Metab. 2010 Oct;11(8):659-66
pubmed: 20942780
Psychopharmacology (Berl). 2019 Sep;236(9):2653-2666
pubmed: 30982127
Brain Behav Immun. 2007 Feb;21(2):161-8
pubmed: 17174524
Front Pharmacol. 2018 Jan 17;8:974
pubmed: 29387009
J Clin Psychopharmacol. 2016 Feb;36(1):77-81
pubmed: 26650973
J Altern Complement Med. 2010 Jan;16(1):3-12
pubmed: 20105062
Brain Behav Immun. 2015 Aug;48:132-8
pubmed: 25770082
Front Hum Neurosci. 2016 Jun 14;10:269
pubmed: 27378878
Prog Brain Res. 2018;242:121-158
pubmed: 30471678
Am J Drug Alcohol Abuse. 2019;45(2):161-169
pubmed: 30822141
Nat Rev Drug Discov. 2018 Jun;17(6):395-412
pubmed: 29725131
J Pers Assess. 1985 Feb;49(1):71-5
pubmed: 16367493
J Biol Chem. 2018 May 4;293(18):6762-6775
pubmed: 29559558
Sci Rep. 2017 Oct 9;7(1):12863
pubmed: 28993683
Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92
pubmed: 16826400
Curr Psychiatry Rep. 2011 Dec;13(6):467-75
pubmed: 21927805
Pharmacol Ther. 2019 May;197:83-102
pubmed: 30521880
Front Immunol. 2015 Jul 14;6:358
pubmed: 26236313
Front Mol Neurosci. 2018 Sep 04;11:312
pubmed: 30233313
Assessment. 2006 Mar;13(1):27-45
pubmed: 16443717
Ann N Y Acad Sci. 2019 Feb;1437(1):57-67
pubmed: 29752710
Am J Physiol Lung Cell Mol Physiol. 2015 Jan 15;308(2):L191-8
pubmed: 25416380
J Psychopharmacol. 2018 Jul;32(7):725-731
pubmed: 29446697
Psychol Med. 2019 Mar;49(4):655-663
pubmed: 29903051
Psychopharmacology (Berl). 2016 Mar;233(5):823-9
pubmed: 26612618
Brain Behav Immun. 2018 May;70:61-75
pubmed: 29499302
J Ethnopharmacol. 1994 Jan;41(1-2):1-8
pubmed: 8170151
J Psychopharmacol. 2016 Dec;30(12):1259-1267
pubmed: 27852960
Sci Rep. 2018 Feb 14;8(1):3031
pubmed: 29445205
Respir Res. 2015 Dec 03;16:145
pubmed: 26635226
BMB Rep. 2015 Apr;48(4):209-16
pubmed: 25560699
Psychopharmacology (Berl). 2018 Oct;235(10):2979-2989
pubmed: 30105399
Br J Clin Psychol. 2005 Jun;44(Pt 2):227-39
pubmed: 16004657
PLoS One. 2010 Aug 31;5(8):e12412
pubmed: 20824211

Auteurs

Malin V Uthaug (MV)

Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands. malin.uthaug@maastrichtuniversity.nl.

Rafael Lancelotta (R)

Innate Path, Lakewood, CO, USA.

Attila Szabo (A)

NORMENT, Institute of Clinical Medicine, University of Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Alan K Davis (AK)

College of Social Work, The Ohio State University, Columbus, OH, 43210, USA.
Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, 21224, USA.

Jordi Riba (J)

Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands.

Johannes G Ramaekers (JG)

Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands. j.ramaekers@maastrichtuniversity.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH